Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Alder Biopharmaceuticals

- PMLiVE

Eli Lilly’s GIP/GLP-1 receptor agonist tirzepatide shows promise in fatty liver disease MASH

Metabolic dysfunction-associated steatohepatitis is the second most common contributor to liver transplantation in the US

- PMLiVE

Eli Lilly’s Alzheimer’s drug unanimously endorsed by FDA panel of experts

The company is seeking approval of donanemab to treat patients with early stages of the disease

- PMLiVE

Amgen’s Uplizna shows promise in rare fibroinflammatory disease IgG4-RD

The company is planning to file for US approval of the CD19-targeted drug in this patient population

- PMLiVE

Eli Lilly gains rights to QurAlis’ neurodegenerative disease therapy in deal worth over $620m

The agreement gives the company global rights to QRL-204 and other UNC13A-targeting compounds

- PMLiVE

Eli Lilly commits further $6.5m to UNICEF for young people at risk of noncommunicable diseases

The new funding builds on the company’s initial commitment of $14.4m in 2022

- PMLiVE

Amgen’s interchangeable Soliris biosimilar Bkemv approved by FDA for rare blood disorders

Bkemv has been authorised to treat paroxysmal nocturnal haemoglobinuria and atypical haemolytic uraemic syndrome

- PMLiVE

Eli Lilly to invest additional $5.3bn totalling $9bn in US manufacturing sites

The investment will provide an additional 200 jobs and more than 5,000 construction jobs during development of the site

- PMLiVE

Novartis shares positive late-stage results for Fabhalta in rare kidney disease C3 glomerulopathy

Approximately one to two people per million worldwide are diagnosed with C3G every year

- PMLiVE

Eli Lilly shares positive late-stage results for mirikizumab in Crohn’s disease

Nearly one in every 100 people in the US are diagnosed with inflammatory bowel disease

- PMLiVE

Eli Lilly and Aktis enter $1bn partnership to develop anticancer radiopharmaceuticals

Lilly will gain rights to develop Aktis’ lead programme targeting a tumour-associated antigen

- PMLiVE

Amgen’s Imdelltra granted FDA accelerated approval to treat small cell lung cancer

More than 234,000 new cases of lung cancer are expected to be diagnosed in the US this year

- PMLiVE

Eli Lilly shares promising phase 3 results for once-weekly insulin efsitora in type 2 diabetes

It is hoped that a once-weekly treatment option could lead to improved adherence

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links